INDY 500 Engineer Experience Sweeptakes Official Rules

OFFICIAL RULES
NO PURCHASE NECESSARY TO ENTER OR WIN. A PURCHASE OR PAYMENT OF ANY KIND WILL NOT INCREASE YOUR CHANCES OF WINNING

1. INDY 500 Engineer Experience SWEEPSTAKES: How To Enter: Beginning on or around April 10, 2012 at 12:01 AM (ET) through May 14, 2012 at 11:59 PM (ET), go to INDY500.POPULARMECHANICS.COM and complete and submit the entry form pursuant to the on-screen instructions. Winner Selection: Winner will be selected on or around May 14, 2012 in a random drawing from among all eligible entries received. Drawing will be conducted by Popular Mechanics Magazine whose decisions are final. Odds of winning will depend upon the total number of eligible entries received. Prizes & Approximate Retail Value: One (1) grand prize winner. One (1) grand prize winner will receive an Indy 500 Engineer Experience package, described as an exclusive behind the scenes view into Indy 500 engineer events in Indianapolis, Indiana in May 2012 which includes the following: two (2) tickets in a three (3)-day suite package to Miller Lite Carb Day?, Legends Day, Indianapolis 500? Mile Race, (ARV: $2,300); a tour for two (2) people of the inner workings of timing and scoring on race day (ARV: $300); Two (2) VIP Access Pit Passes (must be 18 years or older) (ARV: $300); three (3) -night hotel stay for two (2) (May 25th-May 27th) at the JW Marriot (one room, double occupancy) (ARV: $1,200); Total ARV of All Prizes: $ 4,100 (value may vary depending on the cost of travel accommodations). If the winner is unable to attend the event or does not respond to winner notification or return a signed affidavit within two (2) business days of notification by the Sponsor, then the prize will be forfeited and an alternative winner will be selected. Hotel accommodations provided at Sponsor?s discretion. Blackout dates may apply. All travelers must possess valid travel documents. Once scheduled, the itinerary cannot be altered. In the event Indy 500 race/party, or Pit Access is cancelled, the Sponsor reserves the right to award the remainder of the prizes to the grand prize winner. Winners will be notified via phone, e-mail or postal mail, at Sponsor?s discretion, on or about May 14, 2012. Winner?s List: For winner?s name, send a separate self-addressed, stamped envelope to Indy 500 Party Package Sweepstakes Winner List, 200 W 57th St, 17th FL, New York, NY 10019 by July 14, 2012. Entry forms that have been tampered with will be disqualified.

2. ENTRIES: Limit (1) one entry per household for the Indy 500 Engineer Experience SWEEPSTAKES (referred to as the ?Promotion?). Multiple entries from the same household will be disqualified. Entries using macro, robotic, script or other forms of automatic entry will be disqualified. Entries become the property of the Sponsor and will not be returned. Proof of submission does not constitute proof of receipt. If there is a dispute as to the identity of entrant, the prize will be awarded to the authorized account holder of the email address. The ?authorized account holder? is defined as the natural person to whom the email address is assigned by an internet service provider, online service provider or other organization (e.g., business, educational institution, etc.) that is responsible for assigning email addresses for the domain associated with the submitted email address.

3. ELIGIBILITY: Open to legal residents of the 50 United States and the District of Columbia, ages 18 to 29 years of age at the time of entry. Void in Puerto Rico and where prohibited by law. Employees of Sponsor, Indy 500, their parents, affiliates and subsidiaries, participating advertising and promotion agencies and prize suppliers (and members of their immediate family and/or those living in the same of household of each such employee) are not eligible.

4. CONDITIONS OF PARTICIPATION: Entrants must have valid e-mail address and it is entrant?s responsibility to update Sponsor of any change in e-mail address. Expenses not specifically included in prize description and all taxes are the sole responsibility of the winner. Each prize is awarded ?as is? with no warranty or guarantee, either express or implied outside of manufacturer's limited warranty. No transfer, assignment or substitution of a prize permitted, except Sponsor reserves the right to substitute prize for an item of equal or greater value in the event an advertised prize is unavailable. All federal, state, provincial and local laws and regulations apply. Entrants agree to be bound by the terms of these Official Rules and by the decisions of Sponsor, which are final and binding on all matters pertaining to this Promotion. Winners (and parent or legal guardian if winner is a minor) may be required to sign and return an Affidavit of Eligibility, a Liability Release and where legally permissible a Publicity Release within two (2) days following the date of first attempted notification. Failure to comply with this deadline may result in forfeiture of the prize and selection of an alternate winner. Return of any prize/prize notification as undeliverable may result in disqualification and selection of an alternate winner. Acceptance of the prize constitutes permission for Sponsor and its agencies to use winner?s name and/or likeness, biographical material and/or entry (including an altered form of the entry) for advertising and promotional purposes without additional compensation, unless prohibited by law. By accepting prize, winner agrees to hold Sponsor, Relativity, their advertising and promotion agencies and their respective parent companies, subsidiaries, affiliates, partners, representative agents, successors, assigns, officers, directors, and employees harmless for any injury or damage caused or claimed to be caused by participation in the Promotion or acceptance or use of the prize. Sponsor is not responsible for any printing, typographical, mechanical or other error in the printing of the offer, administration of the Promotion or in the announcement of the prize. Winner and guest must sign affidavit of eligibility and W-9 as well as Indy 500?s waiver to redeem the prize package.

5. INTERNET: Sponsor is not responsible for electronic transmission errors resulting in omission, interruption, deletion, defect, delay in operations or transmission, theft or destruction or unauthorized access to or alterations of entry materials, or for technical, network, telephone equipment, electronic, computer, hardware or software malfunctions or limitations of any kind, or inaccurate transmissions of or failure to receive entry information by Sponsor or presenter on account of technical problems or traffic congestion on the Internet or at any Web site or any combination thereof. If for any reason the Internet portion of the program is not capable of running as planned, including infection by computer virus, bugs, tampering, unauthorized intervention, fraud, technical failures, or any other causes which corrupt or affect the administration, security, fairness, integrity, or proper conduct of this Promotion, Sponsor reserves the right at its sole discretion to cancel, terminate, modify or suspend the Promotion. Sponsor reserves the right to select winners from eligible entries received as of the termination date. Sponsor further reserves the right to disqualify any individual who tampers with the entry process. Sponsor may prohibit an entrant from participating in a Promotion if it determines that said entrant is attempting to undermine the legitimate operation of the Promotion by cheating, hacking, deception or other unfair playing practices or intending to abuse, threaten or harass other entrants. Caution: Any attempt by a participant to deliberately damage any Web site or undermine the legitimate operation of the Promotion is a violation of criminal and civil laws and should such an attempt be made, Sponsor reserves the right to seek damages from any such participant to the fullest extent of the law.

6. DISPUTES/CHOICE OF LAW: Except where prohibited, each entrant agrees that: (1) any and all disputes, claims and causes of action arising out of or connected with this Promotion or any prize awarded shall be resolved individually, without resort to any form of class action, and exclusively by state or federal courts situated in New York, NY, (2) any and all claims, judgments and awards shall be limited to actual out-of-pocket costs incurred, but in no event attorneys' fees; and (3) no punitive, incidental, special, consequential or other damages, including without limitation lost profits may be awarded (collectively, "Special Damages"), and (4) entrant hereby waives all rights to claim Special Damages and all rights to have such damages multiplied or increased. New York State law, without reference to New York?s choice of law rules, governs the Promotion and all aspects related thereto.

SPONSOR: The Sponsor of this Promotion is Hearst Communications, Inc., 300 W. 57th Street, New York, NY 10019.

unemployment rate unemployment rate jesse ventura keri russell drew barrymore bill o brien portland trailblazers

Pesticides May Be Linked to Slightly Smaller Babies ... - Health News

By Jenifer Goodwin
HealthDay Reporter

THURSDAY, April 5 (HealthDay News) ? Exposure to a type of pesticide commonly used on crops eaten by U.S. consumers is linked to shorter pregnancies and smaller babies, new research says.

The pesticides are known as organophosphates, which kill insects by disrupting their brains and nervous systems. Originally developed as nerve poisons during World War II, they can disrupt human nervous systems as well, according to the U.S. Environmental Protection Agency.

The effects seen in the study were relatively small. Pregnancies for women exposed to higher levels of organophosphates had babies that were, on average, 1/3 pound lighter than women exposed to lower levels of the pesticides, and their pregnancies were about three to four days shorter.

Spread out over millions of babies, however, lighter babies and shorter pregnancies could have serious health consequences, said senior study author Dr. Bruce Lanphear, a clinician scientist at the Child & Family Research Institute at BC Children?s Hospital in Vancouver, British Columbia.

?When we see a [1/3 pound] reduction in birth weight, we have to start to take notice,? Lanphear said. ?For an individual kid, it?s maybe not a big deal, but for a population it can be. If you shift the whole population down [1/3 pound], it can lead to dramatic increases in kids who are very small. What we see is subtle shifts that, across a whole population, could have dramatic effects on the premature rate.?

Prior research also has found that exposure to higher levels of organophosphates during pregnancy is associated with lower IQs and more behavior problems in children.

The study is published in the April 5 online edition of the journal Environmental Health Perspectives.

Use of organophosphates has declined in recent years, but it remains the most commonly used insecticide, said Lanphear, who is also a professor at Simon Fraser University in British Columbia. Prior research has shown that more than 90 percent of pregnant women and children have measurable levels of organophosphate pesticides in their body.

The study included more than 300 pregnant women in the Cincinnati area, including whites and blacks living in urban, suburban and rural areas and representing the full spectrum of socioeconomic status. Twice during pregnancy, women had their urine tested for organophosphate metabolites, or chemicals that result when the pesticides are broken down.

Researchers also tested for or asked about other factors that could influence the health of a pregnancy and fetus, including smoking or exposure to secondhand smoke, race, poverty and maternal depression.

Women whose exposure was in the 85th percentile, meaning they had the most exposure, had smaller babies and shorter pregnancies on average than those in the 15th percentile. Women in the 85th percentile showed evidence of exposure that was 10 times the rate of exposure for women in the 15th.

The reduction in pregnancy length was statistically significant only in white women, while reduction in birth weight was significant only for black women.

The study couldn?t pinpoint the main source of pesticide exposure, but previous research has singled out diet and home pesticide use as leading sources in non-agricultural settings, the authors said.

Commenting on the study, experts voiced mixed opinions.

?This is an important study, part of the ever-accumulating body of evidence that pesticides are hazardous to human health, even at low doses,? said Dr. Kenneth Spaeth, director of the Occupational and Environmental Medicine Center at North Shore-LIJ Health System in New Hyde Park, N.Y. ?We tend to think that the kinds of low-level exposures we get on a regular basis are not harmful, but studies like this help show there is harm, and we need to be much more mindful and rethink how we regulate and understand how these pesticides affect us.?

It?s known that pesticides reach the fetus, ?because we find traces of pesticides in umbilical cord blood,? Spaeth said. ?Pesticides can also accumulate in breast milk, so you get a double whammy for infants who can be exposed in the womb, and then after birth.?

Dr. Michael Katz, interim medical director for the March of Dimes, cautioned against drawing firm conclusions from the study. Although it was carefully designed and conducted, he said, researchers found an association between pesticide exposure and shorter pregnancies and lower birth weights, but they don?t show that the pesticides caused the fetal effects.

That would require a randomized controlled trial, which is unlikely to ever be done because ethical constraints prevent scientists from deliberately exposing kids to pesticides.

In addition, the differences in birth weight and pregnancy length were minor and fall within what are normal variations, Katz added.

?The differences were very small, and there are things that can be statistically significant but aren?t biologically significant,? he said.

Researchers can?t explain why they saw racial differences in the effect on fetuses. Prior research, however, has shown racial differences in how people metabolize toxins, while blacks and whites may be exposed to different organophosphates, experts said.

More information

The U.S. National Institute of Environmental Health Sciences has more on pesticides.

SOURCES: Bruce Lanphear, M.D., M.P.H., clinician scientist, Child & Family Research Institute, BC Children?s Hospital, and professor, health sciences, Simon Fraser University, Vancouver, B.C., Canada; Kenneth Spaeth, M.D., M.P.H., director, Occupational and Environmental Medicine Center, North Shore-LIJ Health System, New Hyde Park, N.Y.; Michael Katz, M.D., interim medical director, March of Dimes; April 5, 2012, Environmental Health Perspectives

Last Updated: April 05, 2012

Copyright ? 2012 HealthDay. All rights reserved.

“do a barrel roll” texas judge texas judge tom brokaw maria shriver andy irons ethan zohn

Home Improvement, Roofing, Roof Restoration and Gutters at very ...

1 Posted by robertmarty (#1531) 5 hours ago (http://www.ghtuk.com)

GHT is leader in the home improvement industry, providing the highest quality of work for roofing, roof restoration, gutters, roughcasting and others services.

Discuss? |? Bury |? Business

harper lee nike nfl uniforms ben and jerrys free cone day tornado in dallas texas the island president the maldives the fray

Britannica's halt of print edition triggers sales

This undated photo provided April 5, 2012, by Chicago-based Encyclopaedia Britannica, shows the 2010 32-volume final print edition of the Encyclopaedia Britannica. Three weeks after announcing it will discontinue its print editions after 244 years, people have been scrambling to buy the last edition. A spokesman says all by 800 of the last 4,000 sets have been sold. (AP Photo/Courtesy Encyclopaedia Britannica)

This undated photo provided April 5, 2012, by Chicago-based Encyclopaedia Britannica, shows the 2010 32-volume final print edition of the Encyclopaedia Britannica. Three weeks after announcing it will discontinue its print editions after 244 years, people have been scrambling to buy the last edition. A spokesman says all by 800 of the last 4,000 sets have been sold. (AP Photo/Courtesy Encyclopaedia Britannica)

CHICAGO (AP) ? It turns out all Encyclopaedia Britannica had to do to breathe new life into the sale of its print edition was to kill it.

Since Britannica announced last month that it was discontinuing its print editions, the Chicago-based company said sales have skyrocketed. It has sold all but 800 of the 4,000 sets of the 32-volume 2010 edition it had left at a Kentucky warehouse, the company said.

"We were averaging about 60 sets a week and the next thing we knew, we were selling 1,050 a week," Britannica spokesman Peter Duckler said Thursday. "When people thought they were going to be around forever there was no rush to buy one and then suddenly, boom, and now there is a scarcity and it's a collector's item."

Britannica announced March 13 that it would stop publishing print editions of its flagship encyclopedia for the first time in 244 years and instead focus on its online encyclopedia.

Duckler said business got so busy after that ? Britannica at one point was selling the print editions at a clip of about two sets per minute ? that a senior vice president and chief marketing officer jumped in and started taking orders over the phone.

The company will likely sell out by the end of the month, Duckler said. He added that Britannica ? which first published its book form encyclopedia in Edinburgh, Scotland, in 1768 ? will hold onto a few sets so they can be displayed somehow or donated to museums.

As they did before the announcement, the sets are selling for $1,395. If that sounds like a lot of money, secondary sellers online are asking more than $3,200 a set for the 2010 edition ? and that's before the company has run out of the ones it has.

Duckler said the sudden spike in sales hasn't prompted anyone at Britannica to rethink the decision to discontinue selling the print edition. Though the scarcity of the 2010 edition may be making it popular, the company has long known that the print sales were never going to come back to anything approaching the peak year of 1990 when 120,000 were sold.

Britannica, which published the first CD-ROM edition in 1989, introduced an online version in 1994. Online versions of the encyclopedia now serve more than 100 million people around the world and are available on mobile devices, the company said.

"It just makes sense to embrace our digital products," he said.

Associated Press

jimmy rollins jimmy rollins let it snow jason trawick jerry lewis tampa bay bucs cowboys

Sales Management Trainee Lower RGV (Enterprise) | Enterprise ...

Regardless of college major or professional experience, nearly 100% of our full-time employees start out in our Management Training Program. This allows everyone to learn our business from the ground up and understand how they play a significant role in seeing it succeed.

Once you've completed your initial orientation and training, you'll be assigned to a branch office in your home area and the hands-on training begins. You'll learn valuable business skills from capable mentors who were once in your shoes. Nearly 100% of all our managers and corporate executives started out as Management Trainees.

During your first year, you will actively participate in everything from sales and marketing and customer service to operations and finance. As you progress, you will be tested and evaluated to determine your proficiency in these areas. Successful completion of these tests and evaluations will result in rewards, pay increases and the opportunity for continued promotions.

As you progress, increasingly more opportunities will become available to you. You can choose, as most people do, to continue your rewarding ascent within our Rental Operations managerial track or you can explore one of many other exciting options including Fleet Services, Human Resources, Car Sales, Accounting, Marketing and more.

Looking for candidates with experience in restaurant management, retail management, account executive, account manager, customer service, commissioned sales, incentive based sales, sales executive, account executive, sales representative, business development, B2B sales, sales coordinator, sales manager, retail manager, restaurant manager who are looking for entry level sales, retail or management opportunities.

Responsibilities:

As a Management Trainee, you are empowered to make business decisions that greatly affect your career as well as the bottom line. You'll gain responsibility for developing new business and maintaining current relationships. You'll be responsible for understanding cost control, reading your branch's P&L statement and understanding what it takes to run a profitable business. You will also learn how to deliver superior customer service. We will teach you how to effectively communicate, influence and interact with all types of customers, vendors and co-workers. You'll learn proper sales techniques to problem solving and conflict management. Those skills will provide you with the opportunity to market to local business partners and build solid, long-lasting relationships with key business decision-makers. In your development to become a successful manager at Enterprise, you'll learn how to mentor, train, develop, manage and promote a staff of your own.

Qualifications:

• Bachelors degree required.

• Must be at least 18 years old.

• Minimum of 12 months of relevant work experience (can be non-concurrent) in professional sales, customer service, or management within a sales or service industry.

• Will consider organizational involvement, inclusive of a leadership level, in lieu of work experience including: Past/Current Military leadership experience; Past/Current Collegiate organization/leadership positions; or Past/Current NCAA student athlete participation.
• Must have a valid driver license with no more than 2 moving violations and/or at-fault accidents on driving record in the past 3 years.
• Must have been licensed to drive for a minimum of one year.

• No drug or alcohol-related conviction on driving record in the past 5 years.

• Must be authorized to work in the United States and not require work authorization sponsorship by our company for this position now or in the future.

• Apart from religious observations must be available to work a full time schedule of approximately 49-52 hours per week. Typical weekday hours of operation (e.g., Monday-Friday; 7:30 a.m. - 6:00 p.m.); Rotating schedule/reduced-hours on weekend (e.g., Saturday; 9:00 a.m. - 12:00 p.m.)

lesotho

Insight: Chasing cheaper cancer drugs

By Ben Hirschler

LONDON | Sun Apr 1, 2012 10:19am BST

LONDON (Reuters) - In a nondescript suburb south of London, tucked away behind a big hospital, Paul Workman and fellow scientists are celebrating victory in the "World Cup" of cancer drug research for their work in discovering a stream of new medicines.

But the win is bitter-sweet. One of the new drugs behind the coveted prize from the American Association for Cancer Research (AACR) has been deemed too costly to use in state-run British hospitals like the one next door.

It is a stark example of the pricing crisis now facing cancer medicines across the globe.

In developed and developing countries alike, patients and governments are struggling to pay for modern drugs that are revolutionizing cancer care but may cost tens of thousands of dollars a year for each patient.

"It's very frustrating," says Workman, who heads up the drug discovery unit at the Institute of Cancer Research (ICR), which is funded in large part by charities.

What is needed, he believes, is a new model that takes advantage of the highly specific nature of modern targeted therapies to slash drug development timelines and costs.

In the long term, Workman is convinced that will happen. But for the moment the world is caught in a pinch point as global drug companies put sky-high price tags on cancer medicines in a bid to recoup development costs for drugs aimed at a relatively small number of cancer sufferers.

The strains are growing - whether in Europe, where austerity has savaged healthcare budgets, or in the United States, where out-of-pocket costs can bankrupt patients, or in the developing world, where price tags of around $5,000 for a month's drug supply are simply out of reach.

INDIA LOSES PATIENCE

India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience.

New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug Nexavar and issuing its first-ever compulsory license, allowing local generic firm Natco Pharma to produce and sell the drug cheaply in India.

In a move to head off the same threat to its patented drugs, Roche, the world's biggest maker of cancer medicines, plans to offer significantly cheaper locally branded versions of two other cancer treatments, Herceptin and MabThera, under an alliance with Emcure Pharmaceuticals.

Further showdowns with Big Pharma seem inevitable. Novartis, for example, is challenging a decision not to grant a patent for its leukemia drug Glivec in a case that will go to the Indian Supreme Court on July 10.

Michelle Childs, head of policy at Medecins Sans Frontieres and a critic of many industry practices, says the approach taken by Big Pharma to date of excluding the vast majority of people living in developing countries - barring a small but growing middle class - is not sustainable.

She expects powerful countries like India and China, both of which have capacity to make cheap generic drugs, to flex their muscles more in future as the battle over access to medicines enters a new phase.

"Traditionally, the focus has been on drugs for infectious diseases like HIV and tuberculosis, but increasingly developing countries are facing a double burden of disease as we see the rise of chronic diseases like cancer and diabetes," she says.

The issue is not confined to poorer countries - as Workman at the ICR knows all too well.

His team spent many years working on a novel prostate cancer pill that won special recognition in the citation for the AACR prize awarded in Chicago on Sunday (April 1), only to find that Britain's National Institute for Health and Clinical Excellence (NICE) considers it too costly to be used.

If the cost-effectiveness watchdog does not change its mind, Zytiga, which is marketed by Johnson & Johnson and costs 2,930 pounds ($4,700) for a month's supply, will be off-limits for Britons on standard state healthcare.

Significantly, NICE also thinks Bayer's Nexavar is too expensive - highlighting the common concerns about costs shared by healthcare authorities in different parts of the globe.

Such tough calls are inevitable when budgets are limited, according to NICE chairman Mike Rawlins, who says it is time to challenge drug companies about the high prices they seek for products that sometimes offer only modest benefits.

$85 BLN SALES BY 2016

The debate over how to price cancer medicines matters intensely for the pharmaceuticals industry and society at large.

Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008 and predicted to top 13 million in 2030, according to the World Health Organisation. Some 70 percent of deaths occur in low- and middle-income countries.

For drugmakers, the disease is a rich seam of sales and profits. Cancer medicines overtook cholesterol fighters as the biggest-selling selling prescription drug class five years ago and sales are set to hit $85 billion in 2016, up from $58 billion last year and a mere $8 billion in 2000, according to consensus forecasts compiled by Thomson Reuters Pharma.

Cancer is particularly attractive commercially as patents expire and profits wane on drugs in other areas.

Privately, though, even some drug company executives wonder if the industry will be charging such high prices in a few years time.

The price tags on a flurry of new entrants have certainly pushed the envelope, with Bristol-Myers Squibb's melanoma treatment Yervoy costing $120,000 for a four-infusion course and Dendreon's Provenge for prostate cancer priced at $93,000 for a three-dose course.

In the United States, some cancer patients have abandoned medical care because of their bills or else face a significant risk of bankruptcy, according to studies presented at the American Society of Clinical Oncology last year.

Europe's more socialized healthcare system creates different strains. Cash-strapped governments have slashed drug prices, racked up close to $20 billion in unpaid bills for treatments and, crucially, are becoming increasingly reluctant to pay for innovative new drugs.

Andrew Witty, chief executive of GlaxoSmithKline, says European governments are making a false economy by delaying the introduction and reimbursement of promising new treatments, especially for cancer, in their short-term drive to save money.

Pfizer CEO Ian Read told Reuters last month there was a serious "disconnect" between the marketplace in Europe and the desire of governments to sustain a vibrant research base. "Europe is not paying its fair share of innovation," Read said.

SMALLER, SMARTER TRIALS

From his office at the ICR behind the Marsden hospital in Sutton, Workman has an unusual vantage point across the cancer landscape. With a staff of 160, his team is as large as the oncology departments of some Big Pharma companies and in the past six years has discovered 16 innovative cancer drugs.

Thanks to rapid advances in genetics, scientists now have a fundamental understanding of the workings of tumor cells that did not exist in the days when toxic chemotherapy was the only tool in the medicine chest.

However, the lion's share of the $1 billion or more it takes to bring a new drug to market is not chewed up by scientists working in the lab but by the cost of running clinical trials. It is the high failure rate of these studies that pushes up the price of those few drugs that do succeed.

Still, there is light at the end of the tunnel. The ability to target modern cancer treatments to the genetic profile of individual patients means trials can now be designed with far fewer patients, reducing costs dramatically.

Workman predicts that in five years the average success rate for a cancer drug starting out in early-stage clinical development will be 50 percent, up from 5 percent now.

"It is no longer a lottery," he says.

"Trials in future will be smaller, quicker and cheaper. The failure rate will go down and the economic model will rebalance. That means the R&D costs that companies need to recoup when they sell a new drug will come down and those savings should be passed on to the patients."

There are already encouraging signs. Roche's new melanoma drug Zelboraf, for example, which is designed for patients with one type of abnormal gene, was approved in 2011 less than five years after the start of its first clinical trials - far shorter than the timescale for most drugs.

Even so, modern cancer drugs are never likely to be affordable to the poor of Asia, Africa and Latin America under the current patent-protected system - one reason why MSF's Childs says governments need to investigate new models for rewarding innovation, possibly via a system of upfront payments.

Back at the ICR, Workman's colleague Johann de Bono, who led much of the clinical research on Zytiga, says it is clear something in the current system has to give:

"I'm a Christian, so human life to me is very valuable. But how do you value a human life? It's very difficult." ($1 = 0.6285 British pounds)

(editing by Janet McBride)

49ers joe flacco 49ers vs giants joe paterno san francisco 49ers san francisco 49ers giants vs 49ers

Henry Ford Macomb Hospital-Warren to stay open for rehab patients

Warren, Mich. -

Henry Ford Health System closed its Henry Ford Macomb Hospital-Warren

Saturday, but will continue rehabilitation services at the Warren hospital.

The inpatient and outpatient rehabilitation services will continue at the facility on E. 10 Mile Road at Schoenherr.? However, the facility will be renamed "Henry Ford Macomb Physical Rehabilitation Center."

Last January, Henry Ford announced it would close the Henry Ford Macomb Hospital-Warren March 31. The hospital had lost more than $70 million over the last five years.

The changes at the Warren hospital led to 53 layoffs.

Patients with questions can click here.

kim zolciak kim zolciak aspirin aspirin 21 jump street the three stooges hungergames